UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis

Neuromuscular disorders : NMD, 2014-03, Vol.24 (3), p.222-226

2014

Link zum Volltext

Verfügbarkeit prüfen

G.P.112

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.828-829

2014

Link zum Volltext

Verfügbarkeit prüfen

P.2.10 A shorter timed walking or running test may be sufficient for testing function in Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.751-752

2013

Link zum Volltext

Verfügbarkeit prüfen

P.14.17 Evaluation of the ability of timed walking tests to quantify function in sporadic inclusion body myositis

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.818-818

2013

Link zum Volltext

Verfügbarkeit prüfen

P.14.16 Longitudinal changes in strength and functional outcomes in sporadic inclusion body myositis

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.818-818

2013

Link zum Volltext

Verfügbarkeit prüfen

P.6.2 Development of a proof-of-concept device using the Microsoft Kinect to assess movement in infants with spinal muscular atrophy

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.770-770

2013

Link zum Volltext

Verfügbarkeit prüfen

T.P.1

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.860-860

2014

Link zum Volltext

Verfügbarkeit prüfen

G.O.16

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.919-920

2014

Link zum Volltext

Verfügbarkeit prüfen

S.P.11 Development of a virtual upper extremity assessment tool for individuals with DMD across the lifespan

Neuromuscular disorders : NMD, 2012-10, Vol.22 (9), p.878-879

2012

Link zum Volltext

Verfügbarkeit prüfen

S.P.3 Diverse walking distances predict functional outcomes in Duchenne Muscular Dystrophy

Neuromuscular disorders : NMD, 2012-10, Vol.22 (9), p.876-876

2012

Link zum Volltext

Verfügbarkeit prüfen

G.O.24

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.922-922

2014

Link zum Volltext

Verfügbarkeit prüfen

G.O.25

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.923-923

2014

Link zum Volltext

Verfügbarkeit prüfen

PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety

European journal of paediatric neurology, 2015-05, Vol.19, p.S69-S69

2015

Link zum Volltext

Verfügbarkeit prüfen

G.P.167

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.855-856

2014

Link zum Volltext

Verfügbarkeit prüfen

G.P.110

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.828-828

2014

Link zum Volltext

Verfügbarkeit prüfen

P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.804-805

2013

Link zum Volltext

Verfügbarkeit prüfen

P.7.16 One year outcome assessment of young boys with DMD using the Bayley-III Scales of Infant and Toddler Development

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.778-778

2013

Link zum Volltext

Verfügbarkeit prüfen

A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design

Molecular genetics and metabolism, 2016-11, Vol.119 (3), p.239-248

2016

Link zum Volltext

Verfügbarkeit prüfen

Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial

Journal of the neurological sciences, 2019-10, Vol.405, p.271-271

2019

Link zum Volltext

Verfügbarkeit prüfen

G.P.112: Pulmonary function is stable through week 120 in patients with Duchenne muscular dystrophy (DMD) treated with exon-skipping drug eteplirsen in phase 2b study

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.828-829

2014

Link zum Volltext

Verfügbarkeit prüfen

T.P.38: Initial validity and test–retest reliability of ACTIVE-seated (Ability Captured Through Interactive Video Evaluation-seated) as an upper extremity outcome in Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.905-905

2014

Link zum Volltext

Verfügbarkeit prüfen

T.P.1: Pilot study evaluating motivation on the performance of timed walking in boys with Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.860-860

2014

Link zum Volltext

Verfügbarkeit prüfen

G.O.16: Reliability and validity of the ACTIVE-mini (Ability Captured Through Interactive Video Evaluation-mini) to quantify infant movement

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.919-920

2014

Link zum Volltext

Verfügbarkeit prüfen

G.O.25: Follistatin Gene Therapy for Becker Muscular Dystrophy

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.923-923

2014

Link zum Volltext

Verfügbarkeit prüfen

G.O.24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9-10), p.922-922

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Neurology
(17)
Female
(2)
Humans
(2)
Indexing In Process
(2)
Life Sciences & Biomedicine
(2)
Male
(2)
Science & Technology
(2)
2-Min Walk Test
(1)
6-Min Walk Test
(1)
Acetylglucosaminidase - Cerebrospinal Fluid
(1)
Acetylglucosaminidase - Genetics
(1)
Aged
(1)
Aged, 80 And Over
(1)
Brain - Diagnostic Imaging
(1)
Brain - Pathology
(1)
Child
(1)
Child, Preschool
(1)
Clinical Neurology
(1)
Clinical Trials As Topic
(1)
Disease Progression
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis

G.P.112

P.2.10 A shorter timed walking or running test may be sufficient for testing function in Duchenne muscular dystrophy

P.14.17 Evaluation of the ability of timed walking tests to quantify function in sporadic inclusion body myositis

P.14.16 Longitudinal changes in strength and functional outcomes in sporadic inclusion body myositis

P.6.2 Development of a proof-of-concept device using the Microsoft Kinect to assess movement in infants with spinal muscular atrophy

T.P.1

G.O.16

S.P.11 Development of a virtual upper extremity assessment tool for individuals with DMD across the lifespan

S.P.3 Diverse walking distances predict functional outcomes in Duchenne Muscular Dystrophy

G.O.24

G.O.25

PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety

G.P.167

G.P.110

P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

P.7.16 One year outcome assessment of young boys with DMD using the Bayley-III Scales of Infant and Toddler Development

A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design

Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial

G.P.112: Pulmonary function is stable through week 120 in patients with Duchenne muscular dystrophy (DMD) treated with exon-skipping drug eteplirsen in phase 2b study

T.P.38: Initial validity and test–retest reliability of ACTIVE-seated (Ability Captured Through Interactive Video Evaluation-seated) as an upper extremity outcome in Duchenne muscular dystrophy

T.P.1: Pilot study evaluating motivation on the performance of timed walking in boys with Duchenne muscular dystrophy

G.O.16: Reliability and validity of the ACTIVE-mini (Ability Captured Through Interactive Video Evaluation-mini) to quantify infant movement

G.O.25: Follistatin Gene Therapy for Becker Muscular Dystrophy

G.O.24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety

Suchergebnisse filtern